Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received a consensus rating of “Hold” from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $14.50.

Several analysts recently commented on BCYC shares. Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a report on Tuesday, March 17th. Jefferies Financial Group upgraded shares of Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Needham & Company LLC decreased their target price on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Finally, Citizens Jmp lowered their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 18th.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the completion of the transaction, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 19,854 shares of company stock worth $128,376. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds have recently bought and sold shares of BCYC. Assetmark Inc. boosted its holdings in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares during the period. Clearstead Advisors LLC increased its holdings in shares of Bicycle Therapeutics by 234.2% during the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the period. Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at approximately $71,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter valued at approximately $70,000. Finally, Vontobel Holding Ltd. acquired a new stake in Bicycle Therapeutics during the fourth quarter worth approximately $71,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Stock Performance

BCYC opened at $5.05 on Friday. The stock’s fifty day simple moving average is $5.37 and its 200 day simple moving average is $6.59. Bicycle Therapeutics has a 1-year low of $4.24 and a 1-year high of $9.55. The stock has a market cap of $352.02 million, a PE ratio of -1.60 and a beta of 1.65.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.71. The firm had revenue of $47.96 million for the quarter, compared to the consensus estimate of $7.08 million. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. Equities analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.